Medpace Holdings, Inc. MEDP

Medpace Holdings, Inc. comes into today’s file with a hard first-quarter rail from SEC EDGAR: revenue from contracts with customers, excluding assessed tax, was $706.6 million for the period ended 31 March 2026, with operating income of $141.5 million and net income attributable to parent of $123.9 million. Diluted earnings per share were $4.28 on 29.0 million diluted shares. That is the centre of the story because it is the part the source pack actually proves.

The business context matters. Medpace is being read here through its filed financials and related-party revenue disclosures, not through an invented product launch or a promotional claim. The service rail is clinical research work, visible in the contract revenue line and in the 10-Q disclosures on related-party customers. The source pack shows revenue, net included $7.3 million with related parties in the three months ended 31 March 2026, compared with $13.8 million in the 2025 period.

The latest filed balance sheet and cash-flow facts give the report its weight. SEC EDGAR lists assets of $2.13 billion, liabilities of $1.53 billion and stockholders’ equity attributable to parent of $598.3 million for the 10-Q period ended 31 March 2026. Cash and cash equivalents were $652.7 million. Net cash provided by operating activities was $151.8 million, while payments to acquire property, plant and equipment were $6.8 million for the same period.

There is no supplied chart route, so this file does not invent candle levels, moving averages or chart signals. The market mechanism available from the rail is the filing mechanism: a current SEC EDGAR company record, the submissions JSON, companyfacts JSON and named filings. Those sources establish the latest parsed financial base and the public-document sequence, but they do not establish today’s trading level or intraday reaction.

The named public developments are filing events: a MEDP Form 4 dated 1 June 2026, a MEDP Form 3 and MEDP 8-K dated 4 June 2026, a MEDP Form 144 dated 28 May 2026, a MEDP 8-K dated 19 May 2026 and a MEDP Form 4 dated 18 May 2026, all on SEC EDGAR. The filings matter because they mark public corporate disclosure activity, but this evidence pack does not parse the underlying line items of those forms beyond their names, dates, sources and URLs.

The related-party detail deserves a place in the main story rather than an appendix. The 10-Q says the company recognised total revenue from LIB of $1.2 million in the three months ended 31 March 2026, compared with $2.2 million in the 2025 period, and total revenue from CinRx of $6.1 million, compared with $11.7 million in the 2025 period. That is a concrete customer-source angle, not a full demand forecast.